Background/Aims: HER2 has been implicated in mammary tumorigenesis as well as aggressive tumor growth and metastasis. Its overexpression is related to a poor prognosis and chemoresistance in breast cancer patients. Although Grb2-associated binding protein 2 (Gab2) is important in the development and progression of human cancer, its effects and mechanisms in HER2-overexpressing breast cancer are unclear. Methods: Clone formation and MTT assays were used to examine cell proliferation. To detect the effect of Gab2 on the stemness of breast cancer cells, we used flow cytometry, a sphere formation assay, realtime PCR, and western blot. An animal model was created to validate the effect of Gab2 on tumor growth in vivo. Tissue slides were analyzed by immunohistochemistry. Results: Knockdown of Gab2 suppressed PI3K/AKT and MAPK/ERK pathway activity. Gab2 ablation also reduced the stemness of HER2-overexpressing breast cancer cells. In vivo, knockdown of Gab2 inhibited tumor growth. Conclusion: This study unveils a potential function of Gab2 in HER2-overexpressing breast cancer cells. Gab2 might be a potential target in the clinical therapy of HER2-overexpressing breast carcinoma.
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Peng
Introduction
Breast cancer is currently the most common tumor in women. The high rate of breast cancer-related deaths and its high metastasis means that breast cancer is now the most common cause of death in women [1, 2] . Between 15% and 23% of breast cancers show amplification and/or overexpression of the human epidermal growth factor receptor-2 (HER2) gene [3] [4] [5] . This receptor is mainly involved in signaling pathways that regulate cell proliferation, differentiation, migration, and apoptosis [6] [7] [8] [9] . HER2 is a member of the epidermal growth factor receptor (EGFR) family of transmembrane tyrosine kinases. Clinical observations indicate that tumors with high levels of HER2 have poor outcomes [10] [11] [12] . HER2 acts as both a prognostic marker and direct therapeutic target [13] .
Treatment strategies that combine surgery with adjuvant chemotherapy can improve survival but patients often eventually acquire resistance to chemotherapeutic agents [14, 15] . However, recent studies showed that trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-miR-21 and 5-fluorouridine may boost the biological and clinical potential of cancer treatment [16] . Several preclinical and clinical studies suggested that both de novo and acquired resistance to chemotherapeutic agents in breast cancers are associated with elevated levels of HER2 [17] [18] [19] . Recently, studies of human breast cancers showed that there is a correlation between HER2 amplification and breast cancer stem cells (BCSCs), also known as cancer stem-like cells or tumor-initiating cells [20] [21] [22] . These cells have been linked to tumor growth, metastasis, recurrence, and chemoresistance [14, [22] [23] [24] [25] .
Grb2-associated binding protein 2 (Gab2) belongs to the Grb-associated binder (Gab) family of scaffolding adapters, which also includes mammalian Gab1 and Gab3, Drosophila DOS, and C. elegans SOC-1 [26] . Gab2 contains a pleckstrin homology domain at the N terminus and proline-rich motifs and multiple tyrosine phosphorylation sites at the C terminus [26, 27] . Gab2 maps to a chromosomal region (11q13) [28] that is frequently amplified in breast cancer cells [29] . Previous results showed that Gab2 is one of a number of genes predicting lymphoid metastasis in breast cancer [30] . Gab2 is upregulated in numerous human malignancies, such as breast cancer [29, 31, 32] , ovarian cancer [33] , liver cancer [34, 35] , and melanoma [36] . Notably, the Gab2 gene is amplified in approximately 10-15% of breast cancers [32] . In several cancers, elevated expression of Gab2 is associated with proliferation, metastasis, and invasion [32, [36] [37] [38] . However, the effects of Gab2 in HER2-overexpressing breast cancer are not clear.
In our study, knockdown of Gab2 inhibited cell proliferation and xenograft tumor growth. Gab2 depletion suppressed the stemness of HER2-overexpressing breast cancer cells. Thus, we demonstrated that Gab2 plays an important role in regulating stemness. This result may have important implications for breast cancer therapy, and Gab2 may be a new target for HER2-overexpressing breast cancer treatment.
Materials and Methods
Cell lines and reagents T47D-control (T47D-ctl) cells were stably transfected with pCMV4 blank plasmid and T47D-HER2 cells were stably transfected with pCMV-HER2 plasmid. HER2 full-length human cDNA was kindly provided by Dr. Dihua Yu (MD Anderson Cancer Center, Houston, TX). The sequences of the HER2 insert in pCMV4 and the HER2 itself were confirmed by sequencing. T47D-HER2-shGab2 cells were stably transfected with pLKO.1 Gab2 short hairpin RNA (shRNA). Lentiviral-based pLKO.1 Gab2 shRNA was purchased from Origene (Rockville, MD). Stable colonies were selected in the presence of 0.750 mg/mL zeocin (Invitrogen, Life Technologies, Carlsbad, CA). HCC1954-control (HCC1954-ctl) cells were transfected with negative control small interfering RNA (siRNA), HCC1954-siHER2 cells were transfected with HER2 siRNA, and HCC1954-siGab2 cells were transfected with Gab2 siRNA. siRNA and negative control siRNA were purchased from Invitrogen. All cell lines were cultured in RPMI 1640 medium (Gibco, Life Technologies) with 10% fetal bovine serum (Gibco, Life Technologies), 100 units/mL penicillin, and 100 μg/mL streptomycin. The cells were maintained in a humidified atmosphere at 37°C and 5% CO 2 .
Western blot analysis Approximately 2 × 10
6 cells of each cell line were prepared overnight in 6-well plates. After the appropriate treatment, the cells were lysed using RIPA buffer. Protein concentrations were determined by the BSA method (Thermo Fisher Scientific, Waltham, MA). Equal amounts of lysate protein (25 μg) were used for sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After gel electrophoresis, the gel was transferred to a nitrocellulose membrane (Millipore, Burlington, MA) for 1 h. The membrane was blocked for 2 h in 5% skim milk at room temperature, then washed three times with Tris-buffered saline with Tween 20 and incubated overnight with the primary antibody at 4°C. Anti-HER2, -Gab2, -AKT, -pAKT, -ERK, -pERK, -c-Myc, -KLF4, -Oct4, -Sox2, and -GAPDH rabbit antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-ALDH1 mouse antibody was purchased from BD Biosciences (Franklin Lakes, NJ). Anti-CD133 rabbit antibody was purchased from Proteintech (Chicago, IL). Next, the membranes were incubated for 1 hour at room temperature with the appropriate secondary antibodies and detected by chemiluminescence.
Real-time quantitative reverse transcription PCR
Cells from each experimental group were collected by centrifugation. Total RNA was isolated by using Trizol (Takara, Dalian, China) according to the manufacturer's protocol. One microgram RNA was reverse transcribed into single-stranded cDNA using the PrimeScript RT Reagent Kit (Takara). Quantitative real-time reverse transcription PCR (qRT-PCR) was performed in a 7500 fast real-time PCR amplifier (QX200, Biorad, USA) using SYBR Green PCR Master Mix (Takara). PCR primers are shown in Table 1 . The PCR cycling conditions were as follows: initial denaturing at 94°C for 30 s followed by 40 cycles of denaturing at 94°C for 5 s, annealing at 56°C for 30 s, and elongation at 72°C for 20s. Relative levels were determined using the 2 −ΔΔCt method and β-actin was used as the internal control. Each sample was run in duplicate and the results are representative of at least three independent experiments.
siRNA transfection
The HER2 and Gab2 siRNA and negative control siRNA were purchased from Invitrogen. The transfection was performed by using Lipofectamine 2000 (Invitrogen, Life Technology) reagent following the manufacturer's instructions. HER2 or Gab2 expression was determined by western blot assay after 48-72 h of HER2 and Gab2 siRNA transfection.
Colony formation assay T47D-ctl, T47D-HER2, T47D-HER2-shGab2, HCC1954-ctl, and HCC1954-siGab2 cells were plated at a low density (5 × 10 2 cells per well) in a 6-well plate and incubated for 10 days at 37°C and 5% CO 2 in a humidified atmosphere. Colonies were then fixed with 2% paraformaldehyde, stained with a 0.05% crystal violet solution (Sigma-Aldrich, St. Louis, MO), and counted under an inverted microscope.
Sphere formation assay
Cell lines were suspended in an appropriate amount of sphere-forming medium containing serum-free Dulbecco's modified Eagle's medium/F-12 (Gibco, Life Technology), B27 (Invitrogen, Life Technology), 20 ng/mL epidermal growth factor (EGF; Sigma-Aldrich), and 20 ng/mL basic fibroblast growth factor (bFGF; BD Biosciences). Single cells were plated in ultralow attachment 96-well plates at a low density of 500 viable cells per well. T47D-ctl, T47D-HER2, T47D-HER2-shGab2, HCC1954-ctl, and HCC1954-siGab2 cells (5 × 10 2 per well) were plated in ultralow attachment 96-well plates. Cells were incubated at 37°C, 95% humidity, and 5% CO 2 for 7-14 days. Images were taken and sphere-forming efficiency was evaluated on day 7. Spheres were photographed at 100× magnification. 
Flow cytometry analysis
For flow cytometry analysis, breast cancer cells in the logarithmic growth phase were digested with 0.25% trypsin and washed three times with phosphate-buffered saline (PBS), followed by re-suspension in 100 µL PBS and staining with anti-CD44-PE (BD Biosciences) and anti-CD24-FITC (eBioscience, San Diego, CA) or with their isotype controls at 4°C for 30 min (with agitation every 5 min). The samples were then washed three times with PBS and finally re-suspended in 500 μL PBS. Flow cytometry analysis was performed on an Accuri TM C6 Flow Cytometer (Genetimes Technology, Shanghai, China). The expression ratio of CD44
+ and CD24 -(CD44 + /CD24 -) in different breast cancer cell lines was calculated from the percentage of CD44
+ and CD24 -subpopulations in the flow cytometry analysis.
Cell proliferation assay
Cell proliferation was measured by an MTT assay. T47D-ctl, T47D-HER2, T47D-HER2-shGab2, HCC1954-ctl, and HCC1954-siGAB2 cells (1 × 10 4 cells per well) were seeded in a 96-well plate in 100 μL volumes and incubated overnight at 37°C with 5% CO 2 . The cells were treated with a series of concentrations of TAM and incubated for 24 h. They were then treated with 10 μL of MTT (0.5 mg/mL) (Sigma-Aldrich) alone and incubated for 4 h at 37°C in a 5% CO 2 incubator. After the medium was removed, 150 µL DMSO (Sigma-Aldrich) was added into each well to dissolve the formazan crystal. The absorbance was measured at 490 nm with a microplate reader.
To plot the cell growth curve, T47D-ctl, T47D-HER2, and T47D-HER2-shGab2 cells were seeded in 96-well plates (3 × 10 3 cells per well). After transfection, an MTT assay was performed to detect cell survival at 1, 2, 3, 4, 5, 6, and 7 days and the optical density was measured at 490 nm. HCC1954-ctl and HCC1954-siGab2 cells were seeded in 96-well plates (5 × 10 3 cells per well). After transfection, an MTT assay was performed to detect cell survival at 24, 48, 72, and 96 h and optical density was measured at 490 nm.
Tumor growth in xenografts
We used 4-week-old ovariectomized female nude mice to generate an experimental orthotopic breast cancer model. Mice were randomly divided into three groups (five mice per group). T47D-ctl, T47D-HER2, and T47D-HER2-shGab2 cells (1 × 10 7 ) suspended in 100 μL of 50% Matrigel (BD Biosciences) were injected into the second left mammary fat pad by subcutaneous injection at the base of the nipple. The mice were treated with estrogen once a week. After the tumor volume reached about 100 mm 3 , the tumor volumes (A × B 2 /2; A being the greatest diameter and B being the diameter perpendicular to A) were measured twice a week by digital calipers. We began to measure the volumes at day 14 after the cell injection. At day 38, the mice were sacrificed and the tumor xenografts were immediately dissected, weighed, stored, and fixed. All animal procedures were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals under the approval of the Specific Pathogen-Free Laboratory Animal Center at Dalian Medical University.
Immunohistochemistry
Tumors were fixed in 4% paraformaldehyde (Sigma-Aldrich) and prepared for histological analysis. Tissue sections were deparaffinized and rehydrated before antigen retrieval and incubation with 1% H 2 O 2 in methanol for 15 min at room temperature to quench endogenous peroxidase. After being blocked with 5% bovine serum albumin, sections were incubated overnight at 4°C with anti-HER2 rabbit monoclonal antibody (1:800 dilution), anti-Sox2 rabbit monoclonal antibody (1:200 dilution) (Cell Signaling Technology), antiGab2 rabbit monoclonal antibody (1:100 dilution), anti-Ki67 rabbit monoclonal antibody (1:500 dilution) (Abcam, Cambridge, MA), and anti-CD133 rabbit monoclonal antibody (1:200 dilution) (Proteintech). Then, a biotinylated anti-mouse or rabbit IgG antibody and an avidin-biotinylated peroxidase complex were applied with 3, 3-diaminobenzidine as a peroxidase substrate to visualize immunoreactivity. A light hematoxylin counterstain was subsequently applied.
Statistical analysis
All statistical analyses were carried out using SPSS 16.0 software (SPSS Inc., Chicago, IL). Variance analyses and square tests were used for the statistical analysis. Quantitative data are presented as the mean ± standard deviation and were analyzed using a two-sided Student's t test; for the statistical evaluation of more than two groups, the ANOVA test was used. *P < 0.05, **P < 0.01, *** P < 0.001.
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Results

Expression of Gab2 is increased in HER2-overexpressing breast cancer cells
To determine whether Gab2 was upregulated with HER2 overexpression, we compared the mRNA and protein levels of HER2 and Gab2 in T47D-ctl and T47D-HER2 (HER2-overexpressing) cells. qRT-PCR results showed that, with an elevated HER2 mRNA level (Fig.  1a) , the expression of Gab2 mRNA was much higher in T47D-HER2 cells than in T47D-ctl cells (Fig. 1b) . Western blot results indicated that Gab2 protein was also significantly increased in T47D-HER2 cells compared with T47D-ctl cells. In contrast, when we knocked down HER2 in T47D-HER2 cells using HER2-siRNA, the expression of Gab2 was reduced (Fig. 1c) . We also examined the protein expression of HER2 and Gab2 in xenografts by immunohistochemistry analysis. As shown in Fig. 1d , the protein expression of HER2 and Gab2 in the group injected with T47D-HER2 cells was much higher compared with the group injected with T47D-ctl cells.
Knockdown of Gab2 decreases the activity of HER2 downstream pathways and reduces cell proliferation
To clarify the role of Gab2 in HER2-overexpressing cells, we analyzed the activation of HER2 downstream pathways and the viability of cell proliferation using T47D-ctl, T47D-HER2, and T47D-HER2-shGab2 cell lines. Western blot results suggested that the levels of pERK and pAKT in HER2-overexpressing cells (T47D-HER2 cells) were much higher than in T47D-ctl cells, whereas when we knocked down Gab2 in T47D-HER2 cells, the levels of pERK and pAKT were reduced (Fig. 2a) . A colony formation assay showed that the colony numbers of T47D-HER2-shGab2 cells were significantly decreased compared with T47D-HER2 cells (Fig. 2b) . A cell growth curve showed that the proliferation of T47D-HER2-shGab2 cells was also suppressed compared with T47D-HER2 cells (Fig. 2c) . 
Gab2 ablation reduces sphere formation in HER2-overexpressing breast cancer cells
Cancer stem cells can be expanded as sphere-like cellular aggregates in sphere medium containing EGF and bFGF. To further determine the role of Gab2 in the stem cell-like phenotype by using T47D-ctl, T47D-HER2 and T47D-HER2-shGab2 cells, a sphere formation assay was performed. The results showed that the sphere formation viability of T47D-HER2 cells was much higher than that of T47D-ctl cells. However, knockdown of Gab2 in T47D-HER2 cells resulted in significantly lower sphere formation numbers (Fig. 3a) . The sphere numbers and diameters were also measured. As shown in Fig. 3b and c, the sphere sizes were smaller with knockdown of Gab2 in T47D-HER2 cells compared with T47D-HER2 cells. The numbers of spheres in T47D-HER2-shGab2 cells were also reduced compared with T47D-HER2 cells.
Downregulation of Gab2 suppresses self-renewal gene expression and reduces CD44
+ / CD24 -populations in HER2-overexpressing breast cancer cells Previous results showed that c-Myc, KLF4, Oct4, and Sox2 are the key stem cell transcription factors (SCTFs) [24] . These self-renewal genes were analyzed by qRT-PCR. As shown in Fig. 4a , the mRNA levels of these SCTFs in T47D-HER2 cells were upregulated -populations. Differences between the two groups were analyzed using t tests. n = 3; *, P<0.05. 
Gab2 plays an important role in human HER2-positive breast cancer cell lines
To directly study the role of Gab2 in human HER2-positive (HER2 + ) breast cancer cell lines, we first profiled Gab2 expression in MCF-7, T47D, and HCC1954 (HER2 + ) cell lines (Fig. 6a) . We observed higher Gab2 levels in the HCC1954 cell line. As expected, knockdown of HER2 reduced the expression of Gab2 in HCC1954 cells (Fig. 6b) . To test whether Gab2 can drive the growth of HER2 + breast cancer, Gab2 siRNA was used to knockdown Gab2 expression (Fig. 6e) . Clone formation (Fig. 6c) and MTT (Fig. 6d) assays revealed that the proliferation of HCC1954-siGab2 cells was suppressed compared with HCC1954-ctl cells. Additionally, when we knocked down Gab2 in HCC1954 cells, the levels of pERK and pAKT were also reduced (Fig. 6e) . To further confirm the role of Gab2 in stem-like cells of HCC1954, a sphere formation assay was used to reveal the function of Gab2. Compared with HCC1954-ctl cells, the sphere sizes and numbers were all decreased in HCC1954-siGab2 cells (Fig. 6f ). Next, we tested the effect of Gab2 on the expression levels of CD44 and CD24 in HCC1954-ctl and HCC1954-siGab2 cells. The CD44
-fraction was decreased (Fig. 6g) . Gab2 also suppressed the protein expression of the self-renewal genes, including c-Myc, KLF4, Oct4, and Sox2, compared with HCC1954-siGab2 cells (Fig. 6h) .
Knockdown of Gab2 significantly reduces xenograft tumor growth and the expression of self-renewal genes in vivo
The effect of Gab2 on tumor growth was further examined in nude mice with human breast tumor xenografts. T47D-ctl, T47D-HER2, and T47D-HER2-shGab2 cells were injected into the mice. As shown in Fig. 7a , a tumor growth chart revealed that the tumor volumes increased rapidly when the mice were injected with T47D-HER2 cells. Knockdown of Gab2 in T47D-HER2 cells significantly inhibited the growth of xenograft tumors. When we extracted the tumors from the mice, the results showed that the tumor volume in mice injected with T47D-HER2-shGab2 cells was much smaller compared with the group injected with T47D-HER2 cells (Fig. 7b) . Furthermore, the expression of self-renewal genes in xenografts was analyzed by western blot and immunohistochemistry. As shown in Fig. 8a , for the Gab2 ablation group, the protein expression of self-renewal genes was decreased compared with the T47D-HER2 cell group. Immunohistochemistry showed that the expression levels of Ki67, Sox2, and CD133 in tumors extracted from the nude mice injected with T47D-HER2-shGab2 cells were much lower compared with tumors injected with T47D-HER2 cells (Fig. 8b) . 
Discussion
Gab2 has been proposed to be a critical regulator of human cancer development and progression. High levels of Gab2 expression have been detected in breast cancer cell lines and primary tumors [32, 39] . Our results also revealed that when the HER2 oncogene was overexpressed or present in T47D and HCC1954 cells, the expression of Gab2 was upregulated. Conversely, knockdown of HER2 by siRNA had the opposite effect (Fig. 1a-c, Fig.  6a and b) . Gab2 expression was also upregulated in xenograft tumors injected with HER2-overexpressing cells (Fig. 1d) . Previous work showed that overexpression of Gab2 in MCF-10A cells increases cell proliferation and alters growth factor dependency [37] . In addition, other results showed that Gab2 promotes the proliferation of mammary cells cooperating with HER2 [40] . Elevated expression of Gab2 has been found in breast tumors induced by HER2 in mice [41] . In transgenic mice, Gab2 is required for efficient HER2-driven mammary tumorigenesis and metastatic spread [32, 41] , and overexpression of Gab2 accelerates HER2-induced mammary tumorigenesis [32] . Gab2 and HER2 are co-amplified in a subset of breast carcinomas, and co-expression of Gab2 with HER2 results in an invasive phenotype and increases the proliferation of MCF-10A mammary cells in a three-dimensional culture system [32] . Our data indicated that cell proliferation was increased in HER2-overexpressing cells (T47D-HER2 cells) and that knockdown of Gab2 in T47D-HER2 cells decreased their cell proliferation (Fig. 2b-c) . Moreover, the proliferation of HCC1954-siGab2 cells was also suppressed compared with HCC1954-ctl cells (Fig. 6c-d) . However, the mechanism underlying the elevated expression of Gab2 in HER2-overexpressing breast cancer cells is still unclear. Further research would be valuable to explore the mechanism in detail.
Scaffolding adapter proteins may play critical roles in coupling/amplifying signals emanating from growth factor receptors [41] . Gab2 appears to have marked effects on the activity of the PI3K/AKT and MAPK/ERK pathways [42] . Higher levels of Gab2 promote [43] . In addition, Gab2 enhances the activity of the PI3K/AKT and MAPK/ERK pathways in ovarian cancer cells [33] . Moreover, Gab2 silencing impairs the growth and migration of H1975 cells by modulating PI3K/AKT signaling in non-small cell lung cancer [44] . Our results indicated that knockdown of Gab2 suppressed the activity of both PI3K/AKT and MAPK/ERK pathways in HER2-overexpressing breast cancer cells (Fig. 2a and Fig. 7e ).
The theory of cancer stem cells, which are also known as cancer stem-like cells or tumor-initiating cells, posits that several cancers, including breast cancer, are hierarchically organized and driven by a population of cells that display stem cell properties [45] [46] [47] . BCSCs, which constitute a small subset of cells in human breast cancers, promote the tumorigenic and metastatic properties of some breast cancers, and a subpopulation of cells expressing the CD44
− phenotype has been reported to represent such stem-like populations [20, 48] . Moreover, the CD44
-breast cancer cell population is enriched in tumor-initiating and chemotherapy-resistant cells. These cells highly express genes involved in invasion and angiogenesis and display activated TGF-β, Hh, and PLAU signaling pathways. The prevalence of CD44
-cells in breast cancer patients indicates a link between high numbers of stem-like cancer cells and metastasis [49, 50] . Recently, several studies indicated that HER2 is an important regulator of the BCSC population in HER2-overexpressing breast cancers [51, 52] . Our results showed that the expression of BCSC-related proteins was upregulated in T47D-HER2 cells compared with control cells. Previous studies also suggested that HER2 overexpression drives mammary carcinogenesis, tumor growth, and invasion through its effects on BCSCs [21] . HER2-overexpressing BCSCs are causally associated with an aggressive phenotype and radiotherapy resistance [19] . HER2 regulates BCSCs through several signaling pathways, such as the PI3K/AKT, Wnt [21, 53] , and MAPK/ERK pathways [54, 55] . In HER2-positive breast cancers, HER2 interacts with CXCR1, which is selectively expressed in BCSCs [56] . These pathways provide potential targets for therapeutic intervention. Our results showed that knockdown of Gab2 reduced the mRNA and protein expression of self-renewal genes both in vitro and in vivo. Furthermore, the sphere formation ability and percentage of CD44 + /CD24
-cells were reduced with Gab2 ablation. Downregulation of Gab2 suppresses tumor growth in xenograft tumor models (Figs. 3-8) .
From the above, we conjecture that the effects of Gab2 on stemness may at least partially be due to suppression of the PI3K/AKT and MAPK/ERK pathways, which are downstream of HER2-induced pathways. Further research is required to explore the mechanism in detail.
Conclusion
This study unveiled a potential function of Gab2 in regulating the stemness of HER2-overexpressing breast cancer cells. Knockdown of Gab2 suppressed mammosphere formation. Gab2 ablation also reduced the expression of self-renewal genes and proteins in vitro and in a xenograft mouse model. These findings indicated that Gab2 might be a potential target in the clinical therapy of HER2-overexpressing breast carcinoma.
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